论文部分内容阅读
作者报告联合应用淋巴因子激活的杀伤(以K)细胞和白细胞介素2(IL-2)或单独应用大剂量IL-2继承性免疫治疗157例被证明标准治疗无效或尚无标准治疗的转移性癌症患者的结果。 108例患者接受127个疗程的LAK细胞加IL-2治疗;49例患者仅接受IL-2治疗。两组患者于治疗前先静脉输注5天IL-2,剂量为10万U/kg,每8小时输注1次。休息2天遂对接受LAK细胞的患者分离淋巴细胞,并培养使之产生LAK细胞。随后在不同的时间内给病人输注LAK细胞,1～2天后给病人静脉
The authors report the combination of lymphokine-activated killer (K) cells and interleukin 2 (IL-2) or the use of high-dose IL-2 alone for the inherited immunotherapy of 157 cases that have been shown to be ineffective as a standard treatment or in the absence of standard treatment The results of sexual cancer patients. 108 patients received 127 courses of LAK cells plus IL-2 therapy; 49 patients received only IL-2 therapy. Two groups of patients received intravenous infusion of IL-2 for 5 days prior to treatment at a dose of 100,000 U/kg, infused once every 8 hours. After 2 days of rest, lymphocytes were isolated from patients receiving LAK cells and cultured to produce LAK cells. Subsequently, LAK cells were infused to the patient at different times, and the patient was given veins 1 to 2 days later.